Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort

BMC Anesthesiology

Research Article

Neil M Dooney¹  Tharapriya Ramkumar¹  Guy L Ludbrook²  Richard N Upton³  Jennifer Ong⁴  Andrew A Somogyi⁵  Marianne J Chapman⁶  Stephanie N O’Connor⁶  Krishnaswamy Sundararajan⁶ 

[1] Department of Anaesthesia, Pain Medicine and Hyperbaric Medicine, Royal Adelaide Hospital, 5000, Adelaide, SA, Australia;Department of Anaesthesia, Pain Medicine and Hyperbaric Medicine, Royal Adelaide Hospital, 5000, Adelaide, SA, Australia;Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia;Department of Anaesthesia, Pain Medicine and Hyperbaric Medicine, Royal Adelaide Hospital, 5000, Adelaide, SA, Australia;Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia;Discipline of Pharmacometrics, Division of Health Sciences, University of South Australia, Adelaide, Australia;Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia;Discipline of Pharmacology, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia;Intensive Care Unit, Royal Adelaide Hospital, Adelaide, Australia;Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia;

关键词: Tramadol;    Subcutaneous;    Pharmacokinetics;    Severely ill;    Healthy subjects;   

DOI  :  10.1186/1471-2253-14-33

 received in 2013-04-26, accepted in 2014-04-15,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundTramadol is an atypical centrally acting analgesic agent available as both oral and parenteral preparations. For patients who are unable to take tramadol orally, the subcutaneous route of administration offers an easy alternative to intravenous or intramuscular routes. This study aimed to characterise the absorption pharmacokinetics of a single subcutaneous dose of tramadol in severely ill patients and in healthy subjects.Methods/designBlood samples (5 ml) taken at intervals from 2 minutes to 24 hours after a subcutaneous dose of tramadol (50 mg) in 15 patients (13 male, two female) and eight healthy male subjects were assayed using high performance liquid chromatography. Pharmacokinetic parameters were derived using a non-compartmental approach.ResultsThere were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).ConclusionsThe similar time to maximum venous concentration and mean residence time suggest similar absorption rates between the two groups. These results indicate that the same dosing regimens for subcutaneous tramadol administration may therefore be used in both healthy subjects and severely ill patients.Trial registrationACTRN12611001018909

【 授权许可】

Unknown   
© Dooney et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.